Dimensional Fund Advisors LP Purchases 62,143 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Dimensional Fund Advisors LP grew its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 86.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 134,353 shares of the company's stock after buying an additional 62,143 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.17% of Trevi Therapeutics worth $553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Summit Investment Advisors Inc. lifted its holdings in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after buying an additional 2,894 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Trevi Therapeutics during the 4th quarter valued at about $49,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Trevi Therapeutics during the 4th quarter valued at about $67,000. Jump Financial LLC acquired a new stake in shares of Trevi Therapeutics during the 4th quarter valued at about $89,000. Finally, Invesco Ltd. raised its stake in shares of Trevi Therapeutics by 21.2% in the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company's stock valued at $97,000 after acquiring an additional 4,133 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TRVI. Oppenheimer raised their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. D. Boral Capital reissued a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reissued a "buy" rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday. B. Riley reissued a "buy" rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price objective for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $17.56.

Trevi Therapeutics Stock Down 2.4%

NASDAQ TRVI traded down $0.15 during trading on Thursday, hitting $6.03. The company's stock had a trading volume of 670,980 shares, compared to its average volume of 1,197,251. The firm has a 50 day moving average price of $6.27 and a 200 day moving average price of $4.72. The firm has a market cap of $602.35 million, a P/E ratio of -13.70 and a beta of 0.62. Trevi Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. On average, equities analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Jennifer L. Good sold 5,263 shares of the business's stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $1,403,599.54. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Farrell Simon sold 81,313 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 18.30% of the company's stock.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.